Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640

Autor:	Howard A. Burris, Hendrik-Tobias Arkenau, Peter Schmid, Erkut Borazanci, Arthur E. Frankel, Andrew Brenner, Emma Dean, Marie O'Farrell, Gerald Steven Falchook, George Kemble, Jeffrey R. Infante, Juanita Lopez, Shubham Pant, William McCulloch, Suzanne F. Jones, Manish R. Patel
Rok vydání:	2016
Předmět:	0301 basic medicine FASN Inhibitor TVB-2640 Cancer Research biology business.industry Tumor cells First in human Cancer treatment 03 medical and health sciences chemistry.chemical_compound Fatty acid synthase 030104 developmental biology 0302 clinical medicine Oncology Biosynthesis chemistry Biochemistry Apoptosis 030220 oncology & carcinogenesis biology.protein Medicine business
Zdroj:	Journal of Clinical Oncology. 34:2512-2512
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.2512
Popis:	2512Background: FASN inhibition is a novel approach to cancer treatment involving selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::95b6aff772075e77ed9f2bf703054c02 https://doi.org/10.1200/jco.2016.34.15_suppl.2512 Zobrazit plný text záznamu